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Welcome to the new RBFAR
This issue marks the beginning of the next stage in 
development for Revista Brasileira de Farmacognosia/Brazilian 
Journal of Pharmacognosy: we begin the partnership with 
Elsevier Publishing, and a new editorial team takes over. 
Some can probably remember the limited scope and vision 
we had when I began as editor-in-chief four years ago; we 
were unsure of what the future would hold for our journal. 
Today, we focus on the hopes and dreams of a bright group of 
Brazilian scientists who can make a difference for us all. The 
editors (AE Linder, A Zampronio, FB da Costa, MW Biavatti, 
MR Duarte, PD Fernades, RN Almeida, and SG Leitao) welcome 
the new associate editors: Paulo Cezar Vieira (UFSCar), Sérgio 
Ricardo Ambrósio (Unifran), Magna Suzana Alexandre Moreira 
(UFAL), and Fabio Boylan (Trinity College Dublin, Ireland), who 
now complement our team of editors.
Over the course of the last 25 years, RBFAR has established 
itself as an important vehicle for publishing scientific research 
in the pharmacognosy field in Brazil, and now we move on to 
become a journal of international scope as well. Our challenge 
is to ensure the continuity of this successful editorial project, 
promoting changes that further invigorate the journal. Our first 
change has been to expand the number of associate editors 
in order to effectively manage the growing number of article 
submissions. The other major change has been to make every 
effort to professionalize the journal, and we have achieved 
that by forming a partnership with Elsevier Publishing, 
placing our articles in the leading full-text scientific data base, 
ScienceDirect®, with more than 2,500 other scientific journals. 
This will certainly increase the visibility of all articles as well 
as the credibility of RBFAR. It will also provide us with the 
possibility to have our journal indexed in other important 
bases that we still have not reached, such as PubMed.
To reach a quality standard, efforts are being made by the 
editors to reduce the length of the reviewing process, resulting 
in a faster response to authors, a more rapid definition of 
rejected manuscripts, and a more timely publication of 
accepted papers. If a submission is judged not to merit peer 
review and is “desk rejected,” its author(s) will hear from us 
within two weeks of submission. However, we understand 
that authors have a right to an explanation for our decisions. 
To help the editors facilitate this process and avoid early 
rejections, we strongly recommend that authors carefully read 
our submission guide. In our new webpage at Elsevier Editorial 
System, authors will have access to all the necessary guidance 
and information they need in order to make submissions.
Finally, we must state that the increasing number of 
manuscripts received in the last year has led us to decrease the 
proportion of those we accept. In addition, we have decided to 
publish a smaller number of articles than we have previously 
published. Thus, from the present time and in 2014, no more 
than twenty articles will be published per issue. 
We are confident that this new phase of the journal will 
lead to consolidated growth not only for the journal but 
also, and more importantly, for research in Brazil’s field of 
Pharmacognosy.
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